Pharmaceutical Technology

SEPTEMBER 10, 2024

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.

Insulin 130

Insulin Trials 130

Pharmaceutical Technology

SEPTEMBER 10, 2024

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.

Insulin 130

Insulin Trials 130

XTalks

NOVEMBER 4, 2024

Cure Research: Moving Toward an Insulin-Free Future JDRF is focused on funding research that is accelerating the development of new treatments for people with T1D — for all ages and stages. “Our before people need insulin therapy), so that it’s possible to intervene with therapies that can stop clinical disease before it starts.”

Insulin 108

Insulin Research Medicine Doctor 108

Pharmaceutical Technology

JANUARY 10, 2023

In addition, market growth will be driven by dapagliflozin (Farxiga) in the SGLT-2I space, and novel GLP-1/GIP Mounjaro (tirzepatide), biosimilar/interchangeable insulins such as insulin lispro and insulin glargine (Basaglar), and the launch of once-weekly insulins icodec and Icosema, forecast for 2024 launch.

Insulin 130

Insulin Marketing Sales Compliance 130

pharmaphorum

APRIL 29, 2022

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying to change that. cases of hypoglycaemia per year with insulin icodec, versus 0.27 In absolute terms, there were 0.73 events for the once-daily drug.

Insulin 98

Insulin Trials Drugs Production 98

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 10, 2024

Published in the journal JAMA, the study compared patients with Type 2 diabetes who were treated with insulin versus patients who were given a class of drug known […]

Insulin 246

Insulin Drugs Clinical Trials Clinical Trials 246

Pharma Times

SEPTEMBER 6, 2024

New treatment could simplify diabetes management for millions

Insulin 142

Insulin Trials 142

XTalks

OCTOBER 28, 2024

Diabetes, a chronic condition marked by high blood glucose levels due to insulin issues, brings complications like heart disease, stroke, neuropathy and diabetic foot ulcers. Abbot also joined Medtronic to pair its sensors with the latter’s automated insulin delivery (AID) systems. million undiagnosed and 115.9 letter gain.

Insulin 105

Insulin FDA Approval Marketing Doctor 105

XTalks

JULY 3, 2023

The treatment is derived from deceased donor pancreatic cells and is indicated for patients who are unable to achieve average blood glucose levels (glycated hemoglobin) with daily insulin injections or with continuous infusion through a pump because of repeated episodes of severe hypoglycemia (low blood sugar).

Insulin 98

Insulin Gene Therapy Gene Regulation 98

BioSpace

JUNE 25, 2023

A year after treatment, Vertex’s VX-880 has eliminated the need for insulin injections in two Type 1 diabetes patients in a Phase I/II clinical trial of its investigational stem cell-based therapy.

Insulin 77

Insulin Trials Clinical Trials Clinical Trials 77

XTalks

JANUARY 16, 2025

Sling Therapeutics has positive topline results from its Phase IIb/III LIDS clinical trial evaluating its oral small-molecule therapy linsitinib for the treatment of thyroid eye disease (TED). Ninety patients in the trial were randomized to receive one of two doses of linsitinib or placebo.

Trials 59

Trials Clinical Trials Clinical Trials Insulin 59

Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. LAI-287 + semaglutide) overview A fixed dose combination of GLP-1 analogue semaglutide and LAI-287, long-acting basal insulin is under development for the treatment of type 2 diabetes.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

pharmaphorum

JANUARY 12, 2023

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.

Insulin 59

Insulin Trials Development Drugs 59

XTalks

NOVEMBER 21, 2024

These gut hormones are released in response to nutrient intake and play a crucial role in the incretin effect, which enhances insulin secretion. Participants were selected based on their prediabetic status, and the trial compared tirzepatide with a placebo.

Sales 105

Sales Insulin Drugs Trials 105

pharmaphorum

OCTOBER 4, 2022

Danish company Novo Nordisk have announced positive results from the ONWARDS 5 phase 3 trial, with once-weekly insulin icodec demonstrating superior reduction of HbA1 in people with type 2 diabetes, in combination with a dosing guide app.

Insulin 59

Insulin Trials Clinical Trials Clinical Trials 59

pharmaphorum

DECEMBER 7, 2023

Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, potentially opening up a whole new avenue of therapy.

Insulin 117

Insulin Trials 117

Pharmaceutical Technology

DECEMBER 27, 2022

Along the way, mergers and acquisitions continued to happen, new drugs and devices got approved, and innovations in the clinical trial industry were introduced. Drug pricing was a hot-button topic, and William Newton found that while e-commerce chains could cut insulin prices , any major change won’t happen overnight.

Clinical Trials 306

Clinical Trials Clinical Trials Trials Vaccination 306

Pharmaceutical Technology

JULY 12, 2022

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy of Vertex for T1D. It has attained proof-of-concept with favourable safety and efficacy data from an ongoing Phase I/II clinical trial which is currently enrolling and dosing participants.

Gene Therapy 276

Gene Therapy Insulin Manufacturing Clinical Trials 276

The Pharma Data

APRIL 28, 2022

Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from daily insulin. events per patient-year exposed to insulin degludec.

Insulin 52

Insulin Trials Clinical Trials Clinical Trials 52

NY Times

NOVEMBER 27, 2021

A new treatment using stem cells that produce insulin has surprised experts and given them hope for the 1.5 million Americans living with the disease.

Insulin 145

Insulin Clinical Trials Clinical Trials Drugs 145

STAT News

SEPTEMBER 29, 2022

Keeping blood glucose in a healthy range requires a constant stream of calculations: counting the carbs in each meal, and then finding the right dose of insulin to balance them out. In the last several years , automated insulin delivery has helped many patients with type 1 diabetes avoid harmful dips and surges in their blood sugar.

Insulin 126

Insulin Clinical Trials Clinical Trials Trials 126

pharmaphorum

AUGUST 20, 2024

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese adults with pre-diabetes.There's plenty of evidence to show that prediabetes – a higher-than-normal blood sugar level resulting from a level of insulin resistance (..)

Insulin 110

Insulin Trials Development Drugs 110

Pharmaceutical Technology

JANUARY 10, 2023

Hailed as a breakthrough, Tzield’s approval marks the first of its kind to be introduced since the discovery of insulin, which won the 1923 Nobel Prize in the category of Physiology or Medicine. These therapies work by reprogramming the immune system, preventing it from attacking and eradicating insulin-producing cells in the pancreas.

Insulin 246

Insulin FDA Approval Research Development 246

Pharmaceutical Technology

DECEMBER 12, 2022

Pipeline therapies within the cardiometabolic space have recently gathered interest following the 20th World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) Hybrid Conference, which took place on 1–3 December.

Compliance 264

Compliance Insulin Marketing Trials 264

BioPharma Reporter

SEPTEMBER 12, 2024

New data from the QWINT clinical trial may get Eli Lilly closer to bringing a once-weekly insulin injection to the US, following the FDAâs rejection of Novo Nordiskâs own weekly insulin formulation earlier this year.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

BioPharma Reporter

JANUARY 29, 2024

Synthetic biology company rBIO has completed all required analytical characterizations of its insulin biosimilar, R-biolin.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

BioSpace

MAY 15, 2024

Eli Lilly’s efsitora alfa, which is meant to be taken weekly instead of multiple times a day, demonstrated non-inferior A1C reduction in a Phase III trial compared to Novo Nordisk’s daily insulin.

Insulin 54

Insulin Trials 54

Pharma Times

DECEMBER 21, 2023

The new guidance followed a review of a clinical trial and real-world evidence by the University of Warwick and Warwick Medical School, funded by the National Institute for Health and Care Research. The new hybrid closed loop systems have proven to be more effective in maintaining healthy blood glucose levels than standard care.

Insulin 122

Insulin Clinical Trials Clinical Trials Production 122

Scienmag

JANUARY 26, 2021

publishers New Rochelle, NY, January 26, 2021–Hybrid closed-loop insulin therapy improved glycemic control in adolescents and young adults with type 1 diabetes. These outcomes, derived from the International Diabetes Closed-Loop (iDCL) Trial, are reported in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT).

Insulin 55

Insulin Trials Gene Therapy Clinical Trials 55

Pharmaceutical Technology

APRIL 28, 2023

FDA approval follows the successful outcomes of the Sustain Forte trial (NCT03989232), the results of which displayed a superior reduction in HbA1c levels with once-weekly semaglutide 2.0mg, in comparison to once-weekly semaglutide 1.0mg, among individuals suffering from type 2 diabetes.

Sales 130

Sales Insulin Marketing FDA Approval 130

BioSpace

OCTOBER 3, 2023

New Phase I/II trial results show that one more type 1 diabetes patient achieved insulin independence after treatment with Vertex Pharmaceuticals’ investigational stem cell therapy VX-880.

Insulin 105

Insulin Trials 105

Rethinking Clinical Trials

AUGUST 22, 2022

The COVID-OUT Trial is a remotely delivered, Phase 3, de-centralized clinical trial at 6 participating institutions to see if Ivermectin, Metformin or Fluvoxamine would prevent severe COVID-19. Initially, the randomization of the trial was 1:1 Metformin or Placebo. The primary outcome of the trial was negative.

Trials 100

Trials Clinical Trials Clinical Trials Insulin 100

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. In the trial, the vaccine was injected directly into the lymph nodes of type 1 diabetic individuals. The DIAGNODE-2 Trial.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

pharmaphorum

SEPTEMBER 22, 2022

Insulin has been used to manage diabetes for a century, and while many advances have been made for people with both type 1 and type 2 diabetes – many more continue to be made. The post How a once-weekly insulin could disrupt diabetes management – the pharmaphorum podcast appeared first on.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

XTalks

SEPTEMBER 2, 2020

NAFLD is part of the metabolic syndrome that is characterized by diabetes, or pre-diabetes (insulin resistance), which includes being overweight or obese, elevated blood lipids such as cholesterol and triglycerides, as well as high blood pressure. VK2809 and the VOYAGE Trial. NASH may result in severe liver scarring and cirrhosis.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Insulin 98

pharmaphorum

MAY 16, 2022

These examined Mounjaro in 5mg, 10mg and 15 mg doses in five clinical trials, used either as a stand-alone therapy or as an add-on to other diabetes medicines. It was also compared to a placebo, a GLP-1 receptor agonist (semaglutide) and two long-acting insulin analogues. more than insulin degludec and 1.0%

FDA Approval 115

FDA Approval Insulin Drugs Hormones 115

BioSpace

MAY 19, 2021

Eli Lilly's SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.

Insulin 45

Insulin Trials 45